KLCM Advisors Inc. Grows Stake in Johnson & Johnson (NYSE:JNJ)

KLCM Advisors Inc. lifted its position in Johnson & Johnson (NYSE:JNJFree Report) by 11.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,480 shares of the company’s stock after acquiring an additional 646 shares during the quarter. KLCM Advisors Inc.’s holdings in Johnson & Johnson were worth $1,004,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. GW&K Investment Management LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at $35,000. Dark Forest Capital Management LP boosted its position in Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. bought a new position in Johnson & Johnson in the fourth quarter worth about $42,000. Kepos Capital LP purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $45,000. Finally, 25 LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $55,000. 68.40% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $163.73 on Thursday. The stock’s 50-day simple moving average is $166.68 and its 200-day simple moving average is $161.52. The firm has a market capitalization of $425.53 billion, a PE ratio of 33.14, a price-to-earnings-growth ratio of 2.76 and a beta of 0.54. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.59 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 10.75 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.91%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.

Analysts Set New Price Targets

JNJ has been the subject of several analyst reports. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. StockNews.com initiated coverage on Johnson & Johnson in a research note on Thursday, August 17th. They set a “strong-buy” rating on the stock. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Citigroup began coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price on the stock. Finally, Atlantic Securities raised their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $171.80.

View Our Latest Research Report on JNJ

Insider Buying and Selling at Johnson & Johnson

In other news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock valued at $7,928,856 in the last ninety days. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.